Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;33(9):1461-80.
doi: 10.1007/s12325-016-0376-8. Epub 2016 Jul 12.

Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany

Marika Plöthner  1 , Dana Ribbentrop  2 , Jan-Phillipp Hartman  2 , Martin Frank  2
Affiliations

Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany

Marika Plöthner et al. Adv Ther. 2016 Sep.

Abstract

Background: The use of targeted therapies has recently increased. Pharmacogenetic tests are a useful tool to guide patient treatment and to test a response before administering medicines. Pharmacogenetic tests can predict potential drug resistance and may be used for determining genotype-based drug dosage. However, their cost-effectiveness as a diagnostic tool is often debatable. In Germany, 47 active ingredients are currently approved. A prior predictive test is required for 39 of these and is recommended for eight. The objective of this study was to review the cost-effectiveness (CE) of pharmacogenetic test-guided drug therapy and compare the application of drugs with and without prior genetic testing.

Methods: A systematic literature review was conducted to identify the CE and cost-utility of genetic tests. Studies from January 2000 until November 2015 were searched in 16 databases including Medline, Embase, and Cochrane. A quality assessment of the full-text publications was performed using the validated Quality of Health Economic Studies (QHES) instrument.

Results: In the majority of the included studies, the pharmacogenetic test-guided therapy represents a cost-effective/cost-saving treatment option. Only seven studies lacked a clear statement of CE or cost-savings, because of uncertainty, restriction to specific patient populations, or assumptions for comparative therapy. Moreover, the high quality of the available evidence was evaluated.

Conclusion: Pharmacogenetic testing constitutes an opportunity to improve the CE of pharmacotherapy. The CE of targeted therapies depends on various factors including costs, prevalence of biomarkers, and test sensitivity and specificity. To guarantee the CE comparability of stratified drug therapies, national and international standards for evaluation studies should be defined.

Keywords: Abacavir; Azathioprine; Carbamazepine; Cetuximab; Cost-effectiveness; Personalized medicine; Pharmacogenetic test; Targeted therapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram of articles identified and evaluated on the basis of inclusion criteria
See this image and copyright information in PMC

References

    1. Alomar MJ. Factors affecting the development of adverse drug reactions (review article) Saudi Pharm J. 2014;22:83–94. doi: 10.1016/j.jsps.2013.02.003. - DOI - PMC - PubMed
    1. US Food and Drug Administration (FDA). Preventable adverse drug reactions: a focus on drug interactions. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources.... Accessed 28 Apr 2016.
    1. Rottenkolber D, Schmiedl S, Rottenkolber M, et al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf. 2011;20:626–634. doi: 10.1002/pds.2118. - DOI - PubMed
    1. Rodríguez-Vicente AE, Lumbreras E, Hernández JM, et al. Pharmacogenetics and pharmacogenomics as tools in cancer therapy. Drug Metabol Personal Ther. 2016;31:25–34. doi: 10.1515/dmpt-2015-0042. - DOI - PubMed
    1. Weng L, Zhang L, Peng Y, Huang RS. Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics. 2013;14:315–324. doi: 10.2217/pgs.12.213. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources